Five-Flavor Sophora flavescens Enteric-Coated Capsules for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Background. Ulcerative colitis (UC), a chronic inflammatory bowel disease, is characterized by abdominal pain, diarrhea, and mucopurulent bloody stool. In recent years, the incidence and prevalence of UC have been increasing consistently. Five-flavor Sophora falvescens enteric-coated capsule (FSEC),...
Gespeichert in:
Veröffentlicht in: | Evidence-based complementary and alternative medicine 2022, Vol.2022, p.9633048-12 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 12 |
---|---|
container_issue | |
container_start_page | 9633048 |
container_title | Evidence-based complementary and alternative medicine |
container_volume | 2022 |
creator | Hou, Wen Bin Sun, Wei Jia Zhang, Xiao Wen Li, Yuan Xi Zheng, You You Sun, Yu Xin Liu, Jian Ping Liu, Zhao Lan |
description | Background. Ulcerative colitis (UC), a chronic inflammatory bowel disease, is characterized by abdominal pain, diarrhea, and mucopurulent bloody stool. In recent years, the incidence and prevalence of UC have been increasing consistently. Five-flavor Sophora falvescens enteric-coated capsule (FSEC), a licensed Chinese patent medicine, was specifically used to treat UC. This review was aimed to assess the effectiveness and safety of FSEC for the treatment of UC. Methods. Six electronic databases were searched from inception to March 2021. Randomized clinical trials (RCTs) comparing FSEC or FSEC plus conventional Western medicine with conventional Western medicine in participants with UC were included. Two authors screened all references, assessed the risk of bias, and extracted data independently. Binary data were presented as risk ratios (RRs) with 95% confidence intervals (CIs) and metric data as mean difference (MD) with 95% CI. The overall certainty of the evidence was assessed by GRADE. Results. We included 15 RCTs (1194 participants, 763 in the FSEC group and 431 in the control group). The treatment duration ranged from 42 to 64 days. Twelve trials compared FSEC with conventional Western medicine, and two trials compared FSEC plus conventional medicine with conventional medicine. Another trial compared FSEC plus mesalazine with compound glutamine enteric capsules plus mesalazine. FSEC showed a higher clinical effective rate (improved clinical symptoms, colonoscopy results, and stools) (RR 1.12, 95% CI 1.05 to 1.20; 729 participants; 8 trials; low-quality evidence) as well as the effective rate of traditional Chinese medicine (TCM) syndromes (RR 1.10, 95% CI 1.01 to 1.20; 452 participants; 5 trials; low-quality evidence) compared to mesalazine. There was no significant difference in the adverse events between FSEC and control groups. Conclusions. FSEC may show effectiveness in UC treatment compared to conventional medicine, and the use of FSEC may not increase the risk of adverse events. Due to the limited number of clinical trials and low methodological quality of the included trials, our findings must be interpreted with discretion. |
doi_str_mv | 10.1155/2022/9633048 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8769833</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2622087027</sourcerecordid><originalsourceid>FETCH-LOGICAL-c448t-11cae99e45eab108a3069484f731ce05be2c9185bb6192fb8f5c8dfd5ea21fdb3</originalsourceid><addsrcrecordid>eNp9kU2LFDEQhhtR3HX15lkCXgRtN1_dSXsQhmZHhRVhP8BbSKcrTpZ0Z0y6Zxl_hr_YDDMO6sFTVSoPL_XWWxTPCX5LSFWdU0zpeVMzhrl8UJwSwUnJqZQPj734elI8SekOY9oIIR4XJ6zCdW7ZafFz6TZQLr3ehIiuw3oVokY2PyEZGBO6GCeIzpRt0BP0qNXrNHtIyGb81huIesoCqA3eTS69Qwt0vU0TDHls0BVsHNwjPfboM0y6XIzab5NLKFh0ladhcD92ot6NzmiPbqLTPj0tHtlc4NmhnhW3y4ub9mN5-eXDp3ZxWRrO5VQSYjQ0DfAKdEew1Cx74pJbwYgBXHVATUNk1XU1aajtpK2M7G2fcUps37Gz4v1edz13A_TZ7hS1V-voBh23Kmin_v4Z3Up9CxslRd1IxrLAq4NADN9nSJMaXL6a93qEMCdFa0q5IE0lMvryH_QuzDGfY09hKTDdUW_2lIkhpQj2uAzBahe22oWtDmFn_MWfBo7w73Qz8HoPrNzY63v3f7lfAu-0dA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2622087027</pqid></control><display><type>article</type><title>Five-Flavor Sophora flavescens Enteric-Coated Capsules for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>Wiley-Blackwell Open Access Titles</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Hou, Wen Bin ; Sun, Wei Jia ; Zhang, Xiao Wen ; Li, Yuan Xi ; Zheng, You You ; Sun, Yu Xin ; Liu, Jian Ping ; Liu, Zhao Lan</creator><contributor>Chen, Jianping ; Jianping Chen</contributor><creatorcontrib>Hou, Wen Bin ; Sun, Wei Jia ; Zhang, Xiao Wen ; Li, Yuan Xi ; Zheng, You You ; Sun, Yu Xin ; Liu, Jian Ping ; Liu, Zhao Lan ; Chen, Jianping ; Jianping Chen</creatorcontrib><description>Background. Ulcerative colitis (UC), a chronic inflammatory bowel disease, is characterized by abdominal pain, diarrhea, and mucopurulent bloody stool. In recent years, the incidence and prevalence of UC have been increasing consistently. Five-flavor Sophora falvescens enteric-coated capsule (FSEC), a licensed Chinese patent medicine, was specifically used to treat UC. This review was aimed to assess the effectiveness and safety of FSEC for the treatment of UC. Methods. Six electronic databases were searched from inception to March 2021. Randomized clinical trials (RCTs) comparing FSEC or FSEC plus conventional Western medicine with conventional Western medicine in participants with UC were included. Two authors screened all references, assessed the risk of bias, and extracted data independently. Binary data were presented as risk ratios (RRs) with 95% confidence intervals (CIs) and metric data as mean difference (MD) with 95% CI. The overall certainty of the evidence was assessed by GRADE. Results. We included 15 RCTs (1194 participants, 763 in the FSEC group and 431 in the control group). The treatment duration ranged from 42 to 64 days. Twelve trials compared FSEC with conventional Western medicine, and two trials compared FSEC plus conventional medicine with conventional medicine. Another trial compared FSEC plus mesalazine with compound glutamine enteric capsules plus mesalazine. FSEC showed a higher clinical effective rate (improved clinical symptoms, colonoscopy results, and stools) (RR 1.12, 95% CI 1.05 to 1.20; 729 participants; 8 trials; low-quality evidence) as well as the effective rate of traditional Chinese medicine (TCM) syndromes (RR 1.10, 95% CI 1.01 to 1.20; 452 participants; 5 trials; low-quality evidence) compared to mesalazine. There was no significant difference in the adverse events between FSEC and control groups. Conclusions. FSEC may show effectiveness in UC treatment compared to conventional medicine, and the use of FSEC may not increase the risk of adverse events. Due to the limited number of clinical trials and low methodological quality of the included trials, our findings must be interpreted with discretion.</description><identifier>ISSN: 1741-427X</identifier><identifier>EISSN: 1741-4288</identifier><identifier>DOI: 10.1155/2022/9633048</identifier><identifier>PMID: 35069773</identifier><language>eng</language><publisher>United States: Hindawi</publisher><subject>Adverse events ; Bias ; Chinese medicine ; Clinical trials ; Colon ; Colonoscopy ; Data analysis ; Diarrhea ; Disease ; Drug dosages ; Flavor ; Glutamine ; Inflammatory bowel disease ; Inflammatory bowel diseases ; Meta-analysis ; Systematic review ; Traditional Chinese medicine ; Ulcerative colitis</subject><ispartof>Evidence-based complementary and alternative medicine, 2022, Vol.2022, p.9633048-12</ispartof><rights>Copyright © 2022 Wen Bin Hou et al.</rights><rights>Copyright © 2022 Wen Bin Hou et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2022 Wen Bin Hou et al. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c448t-11cae99e45eab108a3069484f731ce05be2c9185bb6192fb8f5c8dfd5ea21fdb3</citedby><cites>FETCH-LOGICAL-c448t-11cae99e45eab108a3069484f731ce05be2c9185bb6192fb8f5c8dfd5ea21fdb3</cites><orcidid>0000-0003-2120-5892 ; 0000-0002-8395-1826 ; 0000-0002-0320-061X ; 0000-0003-2235-3379 ; 0000-0003-2992-1578 ; 0000-0002-4827-9448 ; 0000-0002-0809-1280 ; 0000-0002-1724-4381</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769833/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769833/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,4024,27923,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35069773$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Chen, Jianping</contributor><contributor>Jianping Chen</contributor><creatorcontrib>Hou, Wen Bin</creatorcontrib><creatorcontrib>Sun, Wei Jia</creatorcontrib><creatorcontrib>Zhang, Xiao Wen</creatorcontrib><creatorcontrib>Li, Yuan Xi</creatorcontrib><creatorcontrib>Zheng, You You</creatorcontrib><creatorcontrib>Sun, Yu Xin</creatorcontrib><creatorcontrib>Liu, Jian Ping</creatorcontrib><creatorcontrib>Liu, Zhao Lan</creatorcontrib><title>Five-Flavor Sophora flavescens Enteric-Coated Capsules for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials</title><title>Evidence-based complementary and alternative medicine</title><addtitle>Evid Based Complement Alternat Med</addtitle><description>Background. Ulcerative colitis (UC), a chronic inflammatory bowel disease, is characterized by abdominal pain, diarrhea, and mucopurulent bloody stool. In recent years, the incidence and prevalence of UC have been increasing consistently. Five-flavor Sophora falvescens enteric-coated capsule (FSEC), a licensed Chinese patent medicine, was specifically used to treat UC. This review was aimed to assess the effectiveness and safety of FSEC for the treatment of UC. Methods. Six electronic databases were searched from inception to March 2021. Randomized clinical trials (RCTs) comparing FSEC or FSEC plus conventional Western medicine with conventional Western medicine in participants with UC were included. Two authors screened all references, assessed the risk of bias, and extracted data independently. Binary data were presented as risk ratios (RRs) with 95% confidence intervals (CIs) and metric data as mean difference (MD) with 95% CI. The overall certainty of the evidence was assessed by GRADE. Results. We included 15 RCTs (1194 participants, 763 in the FSEC group and 431 in the control group). The treatment duration ranged from 42 to 64 days. Twelve trials compared FSEC with conventional Western medicine, and two trials compared FSEC plus conventional medicine with conventional medicine. Another trial compared FSEC plus mesalazine with compound glutamine enteric capsules plus mesalazine. FSEC showed a higher clinical effective rate (improved clinical symptoms, colonoscopy results, and stools) (RR 1.12, 95% CI 1.05 to 1.20; 729 participants; 8 trials; low-quality evidence) as well as the effective rate of traditional Chinese medicine (TCM) syndromes (RR 1.10, 95% CI 1.01 to 1.20; 452 participants; 5 trials; low-quality evidence) compared to mesalazine. There was no significant difference in the adverse events between FSEC and control groups. Conclusions. FSEC may show effectiveness in UC treatment compared to conventional medicine, and the use of FSEC may not increase the risk of adverse events. Due to the limited number of clinical trials and low methodological quality of the included trials, our findings must be interpreted with discretion.</description><subject>Adverse events</subject><subject>Bias</subject><subject>Chinese medicine</subject><subject>Clinical trials</subject><subject>Colon</subject><subject>Colonoscopy</subject><subject>Data analysis</subject><subject>Diarrhea</subject><subject>Disease</subject><subject>Drug dosages</subject><subject>Flavor</subject><subject>Glutamine</subject><subject>Inflammatory bowel disease</subject><subject>Inflammatory bowel diseases</subject><subject>Meta-analysis</subject><subject>Systematic review</subject><subject>Traditional Chinese medicine</subject><subject>Ulcerative colitis</subject><issn>1741-427X</issn><issn>1741-4288</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kU2LFDEQhhtR3HX15lkCXgRtN1_dSXsQhmZHhRVhP8BbSKcrTpZ0Z0y6Zxl_hr_YDDMO6sFTVSoPL_XWWxTPCX5LSFWdU0zpeVMzhrl8UJwSwUnJqZQPj734elI8SekOY9oIIR4XJ6zCdW7ZafFz6TZQLr3ehIiuw3oVokY2PyEZGBO6GCeIzpRt0BP0qNXrNHtIyGb81huIesoCqA3eTS69Qwt0vU0TDHls0BVsHNwjPfboM0y6XIzab5NLKFh0ladhcD92ot6NzmiPbqLTPj0tHtlc4NmhnhW3y4ub9mN5-eXDp3ZxWRrO5VQSYjQ0DfAKdEew1Cx74pJbwYgBXHVATUNk1XU1aajtpK2M7G2fcUps37Gz4v1edz13A_TZ7hS1V-voBh23Kmin_v4Z3Up9CxslRd1IxrLAq4NADN9nSJMaXL6a93qEMCdFa0q5IE0lMvryH_QuzDGfY09hKTDdUW_2lIkhpQj2uAzBahe22oWtDmFn_MWfBo7w73Qz8HoPrNzY63v3f7lfAu-0dA</recordid><startdate>2022</startdate><enddate>2022</enddate><creator>Hou, Wen Bin</creator><creator>Sun, Wei Jia</creator><creator>Zhang, Xiao Wen</creator><creator>Li, Yuan Xi</creator><creator>Zheng, You You</creator><creator>Sun, Yu Xin</creator><creator>Liu, Jian Ping</creator><creator>Liu, Zhao Lan</creator><general>Hindawi</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M2M</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2120-5892</orcidid><orcidid>https://orcid.org/0000-0002-8395-1826</orcidid><orcidid>https://orcid.org/0000-0002-0320-061X</orcidid><orcidid>https://orcid.org/0000-0003-2235-3379</orcidid><orcidid>https://orcid.org/0000-0003-2992-1578</orcidid><orcidid>https://orcid.org/0000-0002-4827-9448</orcidid><orcidid>https://orcid.org/0000-0002-0809-1280</orcidid><orcidid>https://orcid.org/0000-0002-1724-4381</orcidid></search><sort><creationdate>2022</creationdate><title>Five-Flavor Sophora flavescens Enteric-Coated Capsules for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials</title><author>Hou, Wen Bin ; Sun, Wei Jia ; Zhang, Xiao Wen ; Li, Yuan Xi ; Zheng, You You ; Sun, Yu Xin ; Liu, Jian Ping ; Liu, Zhao Lan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c448t-11cae99e45eab108a3069484f731ce05be2c9185bb6192fb8f5c8dfd5ea21fdb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adverse events</topic><topic>Bias</topic><topic>Chinese medicine</topic><topic>Clinical trials</topic><topic>Colon</topic><topic>Colonoscopy</topic><topic>Data analysis</topic><topic>Diarrhea</topic><topic>Disease</topic><topic>Drug dosages</topic><topic>Flavor</topic><topic>Glutamine</topic><topic>Inflammatory bowel disease</topic><topic>Inflammatory bowel diseases</topic><topic>Meta-analysis</topic><topic>Systematic review</topic><topic>Traditional Chinese medicine</topic><topic>Ulcerative colitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hou, Wen Bin</creatorcontrib><creatorcontrib>Sun, Wei Jia</creatorcontrib><creatorcontrib>Zhang, Xiao Wen</creatorcontrib><creatorcontrib>Li, Yuan Xi</creatorcontrib><creatorcontrib>Zheng, You You</creatorcontrib><creatorcontrib>Sun, Yu Xin</creatorcontrib><creatorcontrib>Liu, Jian Ping</creatorcontrib><creatorcontrib>Liu, Zhao Lan</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Evidence-based complementary and alternative medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hou, Wen Bin</au><au>Sun, Wei Jia</au><au>Zhang, Xiao Wen</au><au>Li, Yuan Xi</au><au>Zheng, You You</au><au>Sun, Yu Xin</au><au>Liu, Jian Ping</au><au>Liu, Zhao Lan</au><au>Chen, Jianping</au><au>Jianping Chen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Five-Flavor Sophora flavescens Enteric-Coated Capsules for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials</atitle><jtitle>Evidence-based complementary and alternative medicine</jtitle><addtitle>Evid Based Complement Alternat Med</addtitle><date>2022</date><risdate>2022</risdate><volume>2022</volume><spage>9633048</spage><epage>12</epage><pages>9633048-12</pages><issn>1741-427X</issn><eissn>1741-4288</eissn><abstract>Background. Ulcerative colitis (UC), a chronic inflammatory bowel disease, is characterized by abdominal pain, diarrhea, and mucopurulent bloody stool. In recent years, the incidence and prevalence of UC have been increasing consistently. Five-flavor Sophora falvescens enteric-coated capsule (FSEC), a licensed Chinese patent medicine, was specifically used to treat UC. This review was aimed to assess the effectiveness and safety of FSEC for the treatment of UC. Methods. Six electronic databases were searched from inception to March 2021. Randomized clinical trials (RCTs) comparing FSEC or FSEC plus conventional Western medicine with conventional Western medicine in participants with UC were included. Two authors screened all references, assessed the risk of bias, and extracted data independently. Binary data were presented as risk ratios (RRs) with 95% confidence intervals (CIs) and metric data as mean difference (MD) with 95% CI. The overall certainty of the evidence was assessed by GRADE. Results. We included 15 RCTs (1194 participants, 763 in the FSEC group and 431 in the control group). The treatment duration ranged from 42 to 64 days. Twelve trials compared FSEC with conventional Western medicine, and two trials compared FSEC plus conventional medicine with conventional medicine. Another trial compared FSEC plus mesalazine with compound glutamine enteric capsules plus mesalazine. FSEC showed a higher clinical effective rate (improved clinical symptoms, colonoscopy results, and stools) (RR 1.12, 95% CI 1.05 to 1.20; 729 participants; 8 trials; low-quality evidence) as well as the effective rate of traditional Chinese medicine (TCM) syndromes (RR 1.10, 95% CI 1.01 to 1.20; 452 participants; 5 trials; low-quality evidence) compared to mesalazine. There was no significant difference in the adverse events between FSEC and control groups. Conclusions. FSEC may show effectiveness in UC treatment compared to conventional medicine, and the use of FSEC may not increase the risk of adverse events. Due to the limited number of clinical trials and low methodological quality of the included trials, our findings must be interpreted with discretion.</abstract><cop>United States</cop><pub>Hindawi</pub><pmid>35069773</pmid><doi>10.1155/2022/9633048</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-2120-5892</orcidid><orcidid>https://orcid.org/0000-0002-8395-1826</orcidid><orcidid>https://orcid.org/0000-0002-0320-061X</orcidid><orcidid>https://orcid.org/0000-0003-2235-3379</orcidid><orcidid>https://orcid.org/0000-0003-2992-1578</orcidid><orcidid>https://orcid.org/0000-0002-4827-9448</orcidid><orcidid>https://orcid.org/0000-0002-0809-1280</orcidid><orcidid>https://orcid.org/0000-0002-1724-4381</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1741-427X |
ispartof | Evidence-based complementary and alternative medicine, 2022, Vol.2022, p.9633048-12 |
issn | 1741-427X 1741-4288 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8769833 |
source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; Wiley-Blackwell Open Access Titles; PubMed Central; Alma/SFX Local Collection |
subjects | Adverse events Bias Chinese medicine Clinical trials Colon Colonoscopy Data analysis Diarrhea Disease Drug dosages Flavor Glutamine Inflammatory bowel disease Inflammatory bowel diseases Meta-analysis Systematic review Traditional Chinese medicine Ulcerative colitis |
title | Five-Flavor Sophora flavescens Enteric-Coated Capsules for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T13%3A29%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Five-Flavor%20Sophora%20flavescens%20Enteric-Coated%20Capsules%20for%20Ulcerative%20Colitis:%20A%20Systematic%20Review%20and%20Meta-Analysis%20of%20Randomized%20Clinical%20Trials&rft.jtitle=Evidence-based%20complementary%20and%20alternative%20medicine&rft.au=Hou,%20Wen%20Bin&rft.date=2022&rft.volume=2022&rft.spage=9633048&rft.epage=12&rft.pages=9633048-12&rft.issn=1741-427X&rft.eissn=1741-4288&rft_id=info:doi/10.1155/2022/9633048&rft_dat=%3Cproquest_pubme%3E2622087027%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2622087027&rft_id=info:pmid/35069773&rfr_iscdi=true |